Cognitive, Genetic, Brain Volume, and Diffusion Tensor Imaging Markers as Early Indicators of Dementia
- PMID: 32925047
- PMCID: PMC7683082
- DOI: 10.3233/JAD-200445
Cognitive, Genetic, Brain Volume, and Diffusion Tensor Imaging Markers as Early Indicators of Dementia
Abstract
Background: Although associated with dementia and cognitive impairment, microstructural white matter integrity is a rarely used marker of preclinical dementia.
Objective: We aimed to evaluate the individual and combined effects of multiple markers, with special focus on microstructural white matter integrity, in detecting individuals with increased dementia risk.
Methods: A dementia-free subsample (n = 212, mean age = 71.33 years) included in the population-based Swedish National Study on Aging and Care (SNAC-K) underwent magnetic resonance imaging (T1-weighted, fluid-attenuated inversion recovery, diffusion tensor imaging), neuropsychological testing (perceptual speed, episodic memory, semantic memory, letter and category fluency), and genotyping (APOE). Incident dementia was assessed during six years of follow-up.
Results: A global model (global cognition, APOE, total brain tissue volume: AUC = 0.920) rendered the highest predictive value for future dementia. Of the models based on specific markers, white matter integrity of the forceps major tract was included in the most predictive model, in combination with perceptual speed and hippocampal volume (AUC = 0.911).
Conclusion: Assessment of microstructural white matter integrity may improve the early detection of dementia, although the added benefit in this study was relatively small.
Keywords: APOE; cognition; diffusion tensor imaging; magnetic resonance imaging; preclinical dementia; white matter.
Conflict of interest statement
Authors’ disclosures available online (
Figures

References
-
- Jessen F (2014) Subjective and objective cognitive decline at the pre-dementia stage of Alzheimer’s disease. Eur Arch Psychiatry Clin Neurosci 264, 3–7. - PubMed
-
- Winblad B, Amouyel P, Andrieu S, Ballard C, Baryne C, Brodaty H, Cedazo-Minguez A, Dubois B, Edvardsson D, Feldman H, Fratiglioni L, Frisoni GB, Gauthier S, Georges J, Graff C, Iqbal K, Jessen F, Johansson G, Jönsson L, Kivipelto M, Knapp M, Mangialasche F, Melis R, Nordberg A, Rikkert MO, Qiu C, Sakmar TP, Scheltens P, Schneider LS, Sperling R, Tjernberg LO, Waldemar G, Wimo A, Zetterberg H (2016) Defeating Alzheimer’s disease and other dementias: A priority for European science and society. Lancet Neurol 15, 455–532. - PubMed
-
- Elias MF, Beiser A, Wolf PA, Au R, White RF, D’Agostino RB (2000) The preclinical phase of Alzheimer disease: A 22-year prospective study of the Framingham Cohort. Arch Neurol 57, 808–813. - PubMed
-
- Bäckman L, Jones S, Berger AK, Laukka EJ, Small BJ (2005) Cognitive impairment in preclinical Alzheimer’s disease: A meta-analysis. Neuropsychology 19, 520–531. - PubMed
-
- Laukka EJ, Jones S, Small BJ, Fratiglioni L, Bäckman L (2004) Similar patterns of cognitive deficits in the preclinical phases of vascular dementia and Alzheimer’s disease. J Int Neuropsychol Soc 10, 382–391. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous